An increased percentage of myeloid CD34+ bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups.

International Journal of Laboratory Hematology
T-H Chen-LiangAndrés Jerez

Abstract

The Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes (MDS) has established an intermediate category where a disease-modifying intervention is a matter of debate. Flow cytometry allows us to determine a fraction of immature myeloid cells in a semiautomated procedure. The aim of this study, mirroring IPSS-R study inclusion criteria, was to test whether bone marrow (BM) CD34+My percentage has independent prognostic value in the MDS setting. BM CD34+My cells were quantified, at diagnosis, selecting CD34+/CD45+/CD11b±/CD13+. Patients were excluded when receiving treatment for altering the natural course of the disease and when IPSS-R could not be calculated due to the lack of metaphases. Finally, Cox analyses were performed, on a series of 260 patients, for overall survival (OS) and time to acute myeloid leukemia (AML) transformation. By analyzing ROC curves, the most accurate prognostic variable, regarding blasts by cytology and CD34+ by cytometry, was the percentage of blasts by microscopy. The percentage of CD34+My in BM showed an AUC of 0.767 and 0.576 for time to AML transformation and OS, respectively. When performing a multivariate regression including the IPSS-R and the percentage of BM ...Continue Reading

References

Mar 10, 1999·Leukemia Research·F RamosA Orfao
May 13, 2006·American Journal of Clinical Pathology·Samuel J PirruccelloPatricia Aoun
Apr 27, 2011·Cytometry. Part B, Clinical Cytometry·Jevon A CutlerMichael R Loken
Jun 30, 2011·European Journal of Haematology·Patrizia FalcoUNKNOWN Piedmont MDS Registry--Italy
Dec 20, 2011·Haematologica·Stefani ParmentierFrank Kroschinsky
Oct 19, 2013·Blood·Mario CazzolaLuca Malcovati
Jun 16, 2017·Cytometry. Part B, Clinical Cytometry·Patricia FontJosé Luis Díez-Martín

❮ Previous
Next ❯

Citations

Oct 15, 2020·Cytometry. Part B, Clinical Cytometry·Yulia O DavydovaValeriy G Savchenko
Jun 3, 2021·Journal of Clinical Medicine·Tzu-Hua Chen-Liang
Dec 22, 2021·Cytometry. Part B, Clinical Cytometry·Ulrika JohanssonTheresia M Westers

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.